Brief Title
HPV-based Screening Among Women 23-29 Years of Age
Official Title
Evaluation of Organized Human Papilloma Virus (HPV) Screening of 23-29-year-old Women
Brief Summary
The aim of the trial is to determine whether organized screening with primary HPV analysis provide higher cancer protection in the age group 23-29 years compared to primary cytology.
Detailed Description
The aim is to investigate whether primary HPV analysis in the organized cell sampling program for women in the age group 23-29 provides higher cancer protection compared to the current method where cell samples are primarily analyzed with cytology. In this study, all women in the age group 23-29 in the Stockholm and Skåne Region of Sweden will participate. Age is defined by year of birth. For 2020, women born 1991-1997 are included. Sampling and collection of samples is the same as for cytology.
Study Type
Interventional
Primary Outcome
Incidence of cervical cancer
Secondary Outcome
Cost-effectiveness of the new screening method
Condition
Human Papilloma Virus
Intervention
HPV testing
Study Arms / Comparison Groups
HPV-based screening
Description: Women 23-29 invited to cervical screening will have their samples analyzed for HPV.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Diagnostic Test
Estimated Enrollment
180000
Start Date
November 16, 2020
Completion Date
December 31, 2038
Primary Completion Date
December 31, 2038
Eligibility Criteria
Inclusion Criteria: - Women ages 23-29 invited to screening. Exclusion Criteria: - Women who do not show up for screening or do not consent.
Gender
Female
Ages
23 Years - 29 Years
Accepts Healthy Volunteers
No
Contacts
Joakim Dillner, MD, PhD, +46 (0) 72-468 24 60, [email protected]
Location Countries
Sweden
Location Countries
Sweden
Administrative Informations
NCT ID
NCT05229679
Organization ID
2020-00053
Responsible Party
Principal Investigator
Study Sponsor
Karolinska Institutet
Study Sponsor
Joakim Dillner, MD, PhD, Principal Investigator, Karolinska University Hospital/Karolinska Institutet
Verification Date
April 2022